Is there a role for incorporating local therapy into the management of oligometastatic EGFR-mutant NSCLC with curative intent?

Do you incorporate local therapy into the management of oligometastatic EGFR-mutant NSCLC?

• Yes, we recommend local therapy before starting TKI
• Yes, we start TKI and then consolidate with local therapy
• No, we start TKI and only give local therapy in the case of oligo-progression
• No, we only treat these cases with systemic therapy